Sekisui Diagnostics Announces Asset Transfer Agreement with ImmBioMed GmbH & Co. KG
March 12, 2018- Sekisui Diagnostics announced today that ImmBioMed Business Consultants GmbH & Co. KG (IBM) will acquire the specialty coagulation assets of Sekisui Diagnostics GmbH under an asset transfer agreement. Located in Pfungstadt, Germany, ImmBioMed is a business management consulting company and provider of laboratory infrastructure to diagnostic companies.
The agreement covers all Sekisui Diagnostics GmbH specialty coagulation assets including select distribution agreements for products from BioMedica Diagnostics, who acquired the specialty coagulation assets of Sekisui Diagnostic’s US based business in December 2016.
ImmBioMed is an innovation, development and marketing consulting company who also distributes in vitro diagnostics to medical laboratories and reagents for industrial and scientific purposes. They will continue to meet all customer needs and the current levels of exceptional service and support, and no interruption in operations is anticipated.
Sekisui Diagnostics GmbH, located in Pfungstadt, Germany, will continue to support the Sekisui product lines for our rapid test, clinical chemistry reagent, point-of-care immunoassay systems, general coagulation and pre-analytical systems materials. Coagulation products are, and will continue to be, a focus area for Sekisui Diagnostics in the IVD segment through our automated coagulation systems. We thank all our customers for their business and loyalty to the specialty coagulation product line over the years.
For more information or to purchase products from IBM call +49 06157 – 9799 685 or email email@example.com
For any inquiries related to this announcement or other Sekisui Diagnostics’ products and services, please contact Lisa Turner at +1-858-777-2660 or email firstname.lastname@example.org